Slide 1: Non-Viral Genetic Medicine Preliminary Data from LEGEND Pivotal Cohort
Non-Viral Genetic Medicine Preliminary Data from LEGEND Pivotal Cohort September 26, 2024 Exhibit 99.2
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). For
Slide 3: Pivotal Study Currently Enrolling Patients
Pivotal Study Currently Enrolling Patients: BCG-Unresponsive High-risk NMIBC with CIS Design: Global, single-arm, open label N ≈ 100 Dosing: 800μg/ml intravesical at weeks 1,2,5,6 Q3M Endpoints: 1° - CR rate at 12-months; 2° - safety and durability 3 To date, LEGEND protocol has not included surgica
Slide 4: Cohort Patient Demographics
Cohort 1 Patient Demographics Baseline characteristic N=21 Gender, n (%) Male 15 (71.4) Female 6 (28.6) Age, years Mean (SD) 72.7 (9.4) Median (range) 74 (59, 92) Age categories, n (%) ≤65 6 (28.6) >65 15 (71.4) ECOG, n (%) 0 19 (90.5) 1 2 (9.5) BCG Doses Median 11 Range 8, 33 Tumor Stage, n (%) T1
Slide 5: Detalimogene was Well-Tolerated in the LEGEND Study
Detalimogene was Well-Tolerated in the LEGEND Study (n = 42*) Any Grade Grade 1 Grade 2 Grade 3 Grade 4/5 Patients with ≥ 1 TRAE 20 (47.6%) 17 (40.5%) 9 (21.4%) 2 (4.8%)* 0 (0) TRAE Reported in >10% patients: Bladder Spasm 8 (19%) 4 (9.5%) 4 (9.5%) 0 (0) 0 (0) Dysuria 9 (21.4%) 8 (19.0%) 1 (2.4%) 0
Slide 6: Detalimogene: Cohort Efficacy Results Show Promising Clinical Activity
Detalimogene: Cohort 1 Efficacy Results Show Promising Clinical Activity Data relate to 3m and 6m efficacy-evaluable patients available as of September 13, 2024 KM = Kaplan-Meier Analysis; CR = Complete Response Any Time 3 Month (n=21) 6 Month (n=17) 6 Month KM Estimate 71% CR Rate 67% CR Rate 47% C
Slide 7: Detalimogene: Designed To Be the First-Choice Therapy
Detalimogene: Designed To Be the First-Choice Therapy 71% CR rate at any time highlights promising activity Promising safety profile observed; no disconnections due to tolerability Convenient product attributes support community use Evolving care paradigm Global expansion expected to further enrollm